MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the commercialization of diagnostic assays for breast cancer and leukemia, today announces the signature of an agreement with ARUP Laboratories to offer JAK2 molecular diagnostic testing in the USA.
According to the terms of the agreement, Ipsogen grants ARUP, a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development, non-exclusive rights, for the US territory, to offer a complete range of assays for the molecular classification and the screening of Myeloproliferative Neoplasms (MPN), a group of leukaemia's caused by JAK2 gene variations that affects more than 100,000 people in the US. Additional terms were not disclosed.
"This agreement with ARUP, reinforces the medical value of the JAK2 test as a diagnostic tool for MPN supported by the World Health Organization (WHO) guidelines and affirms the strong Intellectual Property position of Ipsogen's JAK2 patent portfolio," said Vincent Fert, Chairman and CEO of Ipsogen.
"We are pleased to have ARUP enter into our licensing program. This agreement supports our strategy to fully supply the US JAK2 market through a combination of strategic licensing arrangements and product sales to leading cancer institutions, hospitals, and commercial labs," added Susan Hertzberg, President of Ipsogen Inc.
JAK2 V617F mutation
In 2006, Ipsogen concluded a worldwide exclusive licensing agreement
following the discovery of JAK2 V617F by the INSERM team of Dr. Vainchenker
at Institut Gustave Roussy, Paris, France. This team identified the key role
played by this mutation of the JAK2 gene in the development of MPN such as
Vaquez disease (Polycythemia Vera), Idiopathic Myelofibrose or
|SOURCE Ipsogen SA|
Copyright©2009 PR Newswire.
All rights reserved